Research progress in antibody-drug conjugates for advanced HER2-positive and HER2-low breast cancer
10.12354/j.issn.1000-8179.2025.20241250
- VernacularTitle:HER2阳性和低表达晚期乳腺癌抗体药物偶联物的研究进展
- Author:
Gong WENJING
1
;
Shi XIUQING
;
Sun PING
Author Information
1. 山东省烟台市烟台毓璜顶医院肿瘤内科(山东省 烟台市 264001)
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates(ADCs);
HER2-positive and HER2-low;
advanced breast cancer;
drug resistance mechanisms
- From:
Chinese Journal of Clinical Oncology
2025;52(2):97-101
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common malignant tumor in women worldwide.HER2-positive and HER2-low breast cancers are highly aggressive subtypes with poor prognosis.First-line combination therapies targeting HER2 have significantly improved treatment outcomes for patients with advanced and metastatic breast cancer,but resistance inevitably develops.The emergence of antibody-drug conjugates(ADCs)brings new hope for the treatment of advanced HER2-positive and HER2-low breast cancers.This article analyzes the efficacy and safety of key ADC drugs,including adotrastuzumab emtansine(T-DM1),trastuzumab deruxtecan(DS-8201,T-DXd)and other drugs in the treatment of advanced HER2-positive and HER2-low breast cancers.It also reviews mechanisms of ADC resistance and discusses corres-ponding management strategies,aiming to provide more efficient and personalized treatment options for patients with advanced HER2-pos-itive and HER2-low breast cancers.
